Aquestive Therapeutics promotes Korczynski to chief commercial officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St futures gain as AI enthusiasm eases worries over higher oil prices, yields
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
July 22, 2025 7:00 AM EDTWARREN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (Aquestive or the Company), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the promotion of Sherry Korczynski, from Senior Vice President of Sales and Marketing, to Chief Commercial Officer effective July 22, 2025.
Sherrys promotion reflects her exceptional track record in commercial leadership within the allergy market, said Daniel Barber, President and Chief Executive Officer of Aquestive. Her proven expertise including her strategic oversight of the EpiPen® brand... More
